Patents by Inventor John Q. Trojanowski

John Q. Trojanowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12071474
    Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: August 27, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Kelvin C. Luk, Virginia M. Y. Lee, John Q. Trojanowski, Kurt R. Brunden, Dustin Covell
  • Publication number: 20230235034
    Abstract: The present disclosure provides monoclonal antibodies that selectively bind to pathological tau over native tau. In certain aspects, the antibodies inhibit or minimize propagation of tau aggregates and/or reduce spread of pathological tau in vivo. In other aspects, the disclosure comprises a method of treating, ameliorating, and/or preventing a tauopathy in a subject, comprising administering any one of the antibodies of the disclosure to the subject. In yet other aspects, the disclosure comprises methods of detecting pathological tau using any one of the antibodies of the disclosure.
    Type: Application
    Filed: May 25, 2021
    Publication date: July 27, 2023
    Inventors: Garrett S. Gibbons, Dawn M. Riddle, John Q. Trojanowski, Virginia M.Y. Lee
  • Publication number: 20230167121
    Abstract: Provided are nitrile- and alkyne-substituted {1,2,4,} triazolo {1,5-A} pyrimidine compounds, compositions containing such compounds, and methods for treating a neurodegenerative disease or cancer by administration of such compounds.
    Type: Application
    Filed: April 12, 2021
    Publication date: June 1, 2023
    Inventors: Kurt R. BRUNDEN, John Q. TROJANOWSKI, Amos B. SMITH, III, Virginia M-Y LEE, Carlo BALLATORE, Thibault ALLE
  • Patent number: 11623927
    Abstract: The present disclosure provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Rx-R8 are defined herein. Also provided are compositions comprising a compound described herein and a pharmaceutically effective excipient, methods of stabilizing microtubules in a patient comprising administering to the patient a microtubule-stabilizing amount of a compound described herein, methods of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, and methods of treating a neurodegenerative disease in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: April 11, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Regents of the University of California
    Inventors: Kurt R. Brunden, Virginia M. Y. Lee, John Q. Trojanowski, Carlo Ballatore, Killian Oukoloff, Amos B. Smith, III
  • Publication number: 20230025707
    Abstract: The present disclosure provides in one aspect monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the disclosure provides a method of treating, ameliorating, and/or preventing ?-Synucleopathic disease in a subject, comprising administering any one of the antibodies of the disclosure to the subject. In yet other aspects, the disclosure provides methods of detecting ?-Synuclein fibrils using any one of the antibodies of the disclosure.
    Type: Application
    Filed: November 19, 2020
    Publication date: January 26, 2023
    Inventors: Kelvin C. Luk, Virginia M.Y. Lee, John Q. Trojanowski, Kurt R. Brunden, Dustin Covell
  • Publication number: 20220227772
    Abstract: The present disclosure provides compounds of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1-R6 are defined herein. Also provided are compositions comprising a compound described herein and a pharmaceutically effective excipient, methods of stabilizing microtubules in a patient comprising administering to the patient a microtubule-stabilizing amount of a compound described herein, methods of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, and methods of treating a neurodegenerative disease in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein.
    Type: Application
    Filed: May 7, 2020
    Publication date: July 21, 2022
    Inventors: Carlo BALLATORE, Kurt R. BRUNDEN, Killian OUKOLOFF, Virgina M.Y. LEE, John Q. TROJANOWSKI, Amos B. SMITH, III
  • Publication number: 20220135661
    Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
    Type: Application
    Filed: January 10, 2022
    Publication date: May 5, 2022
    Inventors: Kelvin C. LUK, Virginia M.Y. LEE, John Q. TROJANOWSKI, Kurt R. BRUNDEN, Dustin COVELL
  • Publication number: 20220041698
    Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Kelvin C. LUK, Virginia M.Y. LEE, John Q. TROJANOWSKI, Kurt R. BRUNDEN, Dustin COVELL
  • Patent number: 11220538
    Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: January 11, 2022
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Kelvin C. Luk, Virginia M. Y. Lee, John Q. Trojanowski, Kurt R. Brunden, Dustin Covell
  • Patent number: 11155608
    Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: October 26, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Kelvin C. Luk, Virginia M. Y. Lee, John Q. Trojanowski, Kurt R. Brunden, Dustin Covell
  • Publication number: 20200399269
    Abstract: The present disclosure provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Rx-R8 are defined herein. Also provided are compositions comprising a compound described herein and a pharmaceutically effective excipient, methods of stabilizing microtubules in a patient comprising administering to the patient a microtubule-stabilizing amount of a compound described herein, methods of treating cancer in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein, and methods of treating a neurodegenerative disease in a patient comprising administering to the patient a therapeutically effective amount of a compound described herein.
    Type: Application
    Filed: February 28, 2019
    Publication date: December 24, 2020
    Inventors: Kurt R. BRUNDEN, Virginia M.Y. LEE, John Q. TROJANOWSKI, Carlo BALLATORE, Killian OUKOLOFF, Amos B. SMITH, III
  • Publication number: 20200369752
    Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
    Type: Application
    Filed: August 22, 2018
    Publication date: November 26, 2020
    Inventors: Kelvin C. LUK, Virginia M.Y. LEE, John Q. TROJANOWSKI, Kurt R. BRUNDEN, Dustin COVELL
  • Publication number: 20200062835
    Abstract: The present disclosure provides monoclonal antibodies that bind ?-Synuclein. In certain aspects, the antibodies preferentially bind to ?-Synuclein fibrils over ?-Synuclein monomer. In other aspects, the invention comprises a method of treating ?-Synucleopathic disease in a subject, comprising administering any of the antibodies of the invention to the subject. In yet other aspects, the invention comprises methods of detecting ?-Synuclein fibrils using any of the antibodies of the invention.
    Type: Application
    Filed: May 1, 2018
    Publication date: February 27, 2020
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Kelvin C. LUK, Virginia M.Y. LEE, John Q. TROJANOWSKI, Kurt R. BRUNDEN, Dustin COVELL
  • Publication number: 20170173016
    Abstract: The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds and their use in the treatment of neurodegenerative disorders.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 22, 2017
    Inventors: Carlo Ballatore, Kurt R. Brunden, Adam T. Hoye, Virginia M.Y. Lee, Amos B. Smith, III, John Q. Trojanowski
  • Patent number: 9649317
    Abstract: The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds which are microtubule-stabilizing compounds and their use in the treatment of neurodegenerative disorders, in particular, tauopathies, such as for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration. In addition, the compounds of the invention may be useful for other diseases where tau pathology is a comorbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: May 16, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carlo Ballatore, Kurt R. Brunden, Adam T. Hoye, Virginia M. Y. Lee, Amos B. Smith, John Q. Trojanowski
  • Patent number: 9643919
    Abstract: The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; R1 is H or C1-6alkyl and R2 is H, C1-6alkyl, C1-6alkaryl, aryl, or heteroaryl; and X is O or NH. Tautomers, enantiomers, and diastereomers, as well as pharmaceutically acceptable salt forms, of compounds of formula I are also within the scope of the invention. Methods of preparing and using the compounds of formula I are also described.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: May 9, 2017
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Carlo Ballatore, Kurt R. Brunden, Virginia M. Y. Lee, Amos B. Smith, III, John Q. Trojanowski, Xiaozhao Wang
  • Publication number: 20160031805
    Abstract: The present invention is directed to compounds of formula I: wherein A is n is 0, 1, or 2; m is 0 or 1; R1 is H or C1-6alkyl and R2 is H, C1-6alkyl, C1-6alkaryl, aryl, or heteroaryl; and X is O or NH. Tautomers, enantiomers, and diastereomers, as well as pharmaceutically acceptable salt forms, of compounds of formula I are also within the scope of the invention. Methods of preparing and using the compounds of formula I are also described.
    Type: Application
    Filed: April 3, 2014
    Publication date: February 4, 2016
    Inventors: Carlo BALLATORE, Kurt R. BRUNDEN, Virginia M.Y. LEE, Amos B. SMITH, John Q. TROJANOWSKI, Xiaozhao WANG
  • Patent number: 9133267
    Abstract: Provided is an antibody that selectively binds to an epitope formed by residues 1-11 of A? in an A? oligomer, a method comprising using the antibody to treat a disease characterized by such an A? amyloid deposit in a patient, and kits comprising same.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: September 15, 2015
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Virginia Man-Yee Lee, Edward Lee, John Q. Trojanowski
  • Publication number: 20150224105
    Abstract: The present invention is directed to triazolopyrimidine, phenylpyrimidine, pyridopyridazine, and pyridotriazine compounds which are microtubule-stabilizing compounds and their use in the treatment of neurodegenerative disorders, in particular, tauopathies, such as for example, Alzheimer's disease, frontotemporal lobar degeneration, Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration. In addition, the compounds of the invention may be useful for other diseases where tau pathology is a comorbidity or where microtubule function is compromised, for example, schizophrenia, Parkinson's disease (PD), PD with dementia, Lewy body disease with dementia, and amyotrophic lateral sclerosis.
    Type: Application
    Filed: September 19, 2013
    Publication date: August 13, 2015
    Inventors: Carlo Ballatore, Kurt R. Brunden, Adam T. Hoye, Virginia M.Y. Lee, Amos B. Smith, John Q. Trojanowski
  • Patent number: 8927586
    Abstract: The present invention relates to novel TP receptor antagonists, which optionally cross the blood-brain barrier of a mammal. The invention also provides methods for treating a disorder related to activation of TP receptor utilizing the compounds of the invention.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: January 6, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John Q. Trojanowski, Virginia M. Y. Lee, Kurt R. Brunden, Amos B. Smith, Donna M. Huym, Carlo Ballatore, Anne-Marie Hogan, Francesco Piscitelli, Sugiyama Shimpei, Xiaozhao Wang